• Blog
  • Hospital Injectable Drugs Market Growth Analysis

    Hospital Injectable Drugs Market Growth Analysis

    Hospital Injectable Drugs Market Growth Analysis
    Report code - SR1513 Delivery - 2 Weeks
    Hospital Injectable Drugs Market Growth, Trends, Dynamics & Market Insights: 2022-2028 See more...

    Market Insights

    The Hospital Injectable Drugs Market is projected to grow from USD 40.64 Billion in 2021 to USD 56.51 Billion by 2028 at a CAGR of around 4.79% during the forecast period.

    Wish to get a free sample? Register Here

    What is a hospital injectable drug?

    Hospital injectable drugs can be defined as medications which are introduced into the patient’s body with the help of injections. These drugs are injected directly into the bloodstream with the help of injectable devices such as syringes and needles.

    Hospital Injectable Drugs Market Report Overview

    Market Size in 2028

    USD 56.51 Billion

    Market Size in 2021

    USD 40.64 Billion

    Market Growth (2022-2028)

    CAGR of 4.79%

    Base Year of Study

    2021

    Trend Period

    2017-2020

    Forecast Period

    2022-2028

    Key Players

    Key players operating in the Hospital Injectable Drugs market are-

    • Baxter International Inc. (US)
    • Sanofi S.A. (France)
    • Pfizer Inc. (US)
    • GlaxoSmithKline plc (UK)
    • AstraZeneca plc (UK)
    • Gilead Sciences, Inc. (US)
    • Merck & Co., Inc. (US)
    • Novartis International AG (Switzerland)
    • Johnson & Johnson (US)
    • Novo Nordisk A/S (Denmark)

    Market Dynamics

    The growth of the hospital injectable drugs market is primarily driven by an increasing number of people suffering from chronic diseases and accidental injuries. Expanding the geriatric populace across geographies is expected to drive market growth at a significant rate during the review period. In addition to this, increasing investment in research and development activities to develop advanced healthcare solutions is likely to create lucrative opportunities for the players operating in the global hospital injectable drugs market in the coming years

    COVID-19 Impact

    The COVID-19 outbreak posed significant challenges across verticals worldwide. It impacted the growth of the hospital injectable drugs market negatively as healthcare solutions other than COVID-19 treatment declined due to fear of coronavirus infection. Also, supply chain disruptions due to the imposition of lockdown affected the product availability on time and thus, affected the market growth.

    Wish to get a free sample? Register Here

    Segment Analysis

    This report studies the market covering a period of 12 years of trend and forecast. The report provides detailed insights into the market dynamics to enable informed business decision-making and growth strategy formulation based on the opportunities present in the market.

    The market is segmented into the following categories-

    By Type

    • Generic Sterile Injectables
    • Sterile Intravenous (IV) Solutions

    By Application Type

    • Cardiology & Metabolic disorders
    • Neurology
    • Oncology
    • Autoimmune
    • Gastroenterology
    • Hematology
    • Infectious Diseases
    • Others

    By End-Use Type

    • Hospital Pharmacy
    • Retail Pharmacy
    • E-commerce

    By Region

    • North America
    • Asia-Pacific
    • Europe
    • Rest of the World

    End-User Type

    The market has been bifurcated into hospital pharmacy, retail pharmacy, and e-commerce. The hospital pharmacy segment accounted for the largest market share in 2021 and is projected to register significant growth during the review period. The segment can be attributed to the convenience and easy availability of required drugs.

    Regional Analysis

    North American market accounted for the largest market share in 2021 and is projected to grow at a robust CAGR during the review period. This can be attributed to the high adoption rate of advanced diagnostic equipment coupled with the presence of key market players such as Kemper Medical, Inc. (US) and Chemyx, Inc. (US). The market growth in Asia-Pacific is expected to be driven by the increasing adoption of Hospital Injectable Drugs in diagnostic procedures, particularly in developing countries.

     

    To know which region offers the best growth opportunities, Register Here

    Target Audience

    Here is the list of the group of customers that the hospital inhjectable drugs market hopes to have the greatest opportunity to convert-

    • Distributors
    • Suppliers
    • Manufacturers
    • Logistics organizations
    • Government bodies

    Report Features

    This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

    What deliverables will you get in this report?

    Key questions this report answers

    Relevant contents in the report

    How big is the sales opportunity?

    In-depth analysis of the Hospital Injectable Drugs Market

    How lucrative is the future?

    Market forecast and trend data and emerging trends

    Which regions offer the best sales opportunities?

    Global, regional and country level historical data and forecasts

    Which are the most attractive market segments?

    Market segment analysis and forecast

    Which are the top players and their market positioning?

    Competitive landscape analysis, Market share analysis

    How complex is the business environment?

    Porter’s five forces analysis, PEST analysis, Life cycle analysis

    What are the factors affecting the market?

    Drivers & challenges

    Will I get the information on my specific requirement?

    10% free customization

    Research Methodology

     

    This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

    Customization Options

    With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

    Company Profiling

    • Detailed profiling of additional market players (up to three players)
    • SWOT analysis of key players (up to three players)

    Competitive Benchmarking

    • Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

    Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    Hospital injectable drugs can be defined as the medications which are introduced into the patients body with the help of injections. These drugs are injected directly into the bloodstream with the help of injectable devices such as syringes and needles.

    The hospital injectable drugs market is projected to grow from USD 40.64 billion in 2021 to USD 56.51 billion by 2028.

    The hospital injectable drugs market is expected to witness an impressive growth of 4.79% CAGR in the coming years.

    Baxter International Inc. (US), Sanofi S.A. (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), AstraZeneca plc (UK), Gilead Sciences, Inc. (US), Merck & Co., Inc. (US), Novartis International AG (Switzerland), Johnson & Johnson (US), Novo Nordisk A/S (Denmark).

    The North American market accounted for the largest market share in 2021.

    The growth of the hospital injectable drugs market is primarily driven by an increasing number of people suffering from chronic diseases and accidental injuries. Expanding the geriatric populace across geographies is expected to drive market growth at a significant rate during the review period. In addition to this, increasing investment in research and development activities to develop advanced healthcare solutions is likely to create lucrative opportunities for the players operating in the global hospital injectable drugs market in the coming years.

    The hospital pharmacy segment accounted for the largest market share in 2021.

    By Type (Generic Sterile Injectables, Sterile Intravenous (IV) Solutions), Application (Cardiology & Metabolic disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Infectious Diseases, and Others), End-User (Hospital Pharmacy, Retail Pharmacy, E-commerce), and Region - COVID-19 Impact Analysis and Forecast to 2028.